Characterization of 225Ac-Labeled HER2-Targeting Trastuzumab
| Radiolabeling efficiency (%) | Immunoreactivity (%) | Specific activity* (MBq/mg of antibody) | Radiochemical purity | 24-h retention (%) | KD (nM) | |
|---|---|---|---|---|---|---|
| BT474 | BT474_R | |||||
| 53.8 ± 11.4 (n = 14) | 95.9 ± 1.4 (n = 14) | 3.4 ± 0.7 (n = 11) | 97.8 ± 1.8 (n = 14) | 90.6 ± 2.5 (n = 14) | 24.6 ± 4.9 | 10.2 ± 1.7 |
*Starting activity, 0.4–1.1 MBq
KD = dissociation constant.